--- title: "Rezolute (RZLT) news: offering" url: "https://aibio.space/companies/rezolute/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RZLT offering news: Rezolute sells 1,295,383 shares in private placement for $4,209,994.75. Rezolute, Inc. (NASDAQ: RZLT), United States." --- RZLT Rezolute, Inc. NASDAQ · United States # Rezolute (RZLT) news RZLT offering news Financings · 2025-06-13 ## [Rezolute sells 1,295,383 shares in private placement for $4,209,994.75](https://aibio.space/news/rezolute-sells-1-295-383-shares-private-placement-4-209-994-75/) An 8-K filed June 13, 2025 reports the sale. Certain insiders had agreed in April to buy up to $10,000,000 of stock at $3.25 per share in the private placement. ## Latest Rezolute news 1. 2025-04-23 Financings [Rezolute prices registered direct offering of about $90 million at $3.25 per share](https://aibio.space/news/rezolute-prices-registered-direct-offering-about-90-million-3-25-share/) Rezolute will sell 20,786,923 shares at $3.25 and pre-funded warrants for up to 6,905,385 shares, through Guggenheim Securities as representative of the underwriters. Estimated net proceeds are $84.2 million, and insiders separately agreed to buy up to $10,000,000 of stock at the same price. ## Rezolute at a glance - **Ticker**: RZLT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $107.8 million ### Related companies - [Allarity Therapeutics](https://aibio.space/companies/allarity-therapeutics/) NASDAQ: ALLR - [Accustem Sciences](https://aibio.space/companies/accustem-sciences/) OTC: ACUT - [Inhibikase Therapeutics](https://aibio.space/companies/inhibikase-therapeutics/) NASDAQ: IKT - [Achieve Life Sciences](https://aibio.space/companies/achieve-life-sciences/) NASDAQ: ACHV - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [MacroGenics](https://aibio.space/companies/macrogenics/) NASDAQ: MGNX - [Minerva Neurosciences](https://aibio.space/companies/minerva-neurosciences/) NASDAQ: NERV - [Johnson & Johnson](https://aibio.space/companies/johnson-johnson/) NYSE: JNJ ### Also on NASDAQ - [MetaVia](https://aibio.space/companies/metavia/) MTVA - [Mobia Medical](https://aibio.space/companies/mobia-medical/) MOBI - [Kymera Therapeutics](https://aibio.space/companies/kymera-therapeutics/) KYMR - [Revolution Medicines](https://aibio.space/companies/revolution-medicines/) RVMD - [Dogwood Therapeutics](https://aibio.space/companies/dogwood-therapeutics/) DWTX - [X4 Pharmaceuticals](https://aibio.space/companies/x4-pharmaceuticals/) XFOR ## What Rezolute does Rezolute, Inc. is a late-stage rare disease company developing therapies for refractory and debilitating hypoglycemia associated with hyperinsulinism (HI). Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds an allosteric site on the insulin receptor. The company says it is being developed to treat any form of HI, and that its dose dependent pharmacokinetics have a half-life greater than 2 weeks. The Phase 3 sunRIZE study in congenital HI did not meet its primary endpoint or its key secondary endpoint at the defined Week 24 window, as announced on December 11, 2025. The company reports that continuous glucose monitoring endpoints showed consistent reductions in hypoglycemia compared to placebo, and it shared these data at the Pediatric Endocrine Society Annual Meeting on May 1, 2026. The company met with the FDA on March 17, 2026, under its Breakthrough Therapy Designation. In September 2026 the agency said it was still reviewing the submission, and the text states that there is no specific timeline for feedback. An open-label extension is ongoing, with 56 participants remaining in it. | Product or program | What it is | Stage | |---|---|---| | ersodetug | Allosteric insulin receptor antibody for refractory hypoglycemia caused by hyperinsulinism | Phase 3 sunRIZE did not meet primary endpoint; FDA reviewing submission | Summarised from the company's [10-K filed Sep 24, 2026](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm). ## Rezolute annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Research and development | [$53.8 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | [$61.5 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | | Net income (loss) | [-$77.6 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | [-$74.4 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | | Cash from operations | [-$64.6 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | [-$69.1 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | | Cash and equivalents | [$10.6 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | [$94.1 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | | Short-term investments | [$97.2 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | [$73.8 million](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/) | Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $10.6 million, plus short-term investments of $97.2 million, $107.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Rezolute Has Rezolute raised money recently? Our latest story on this, dated Jun 13, 2025: "Rezolute sells 1,295,383 shares in private placement for $4,209,994.75". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/rezolute-sells-1-295-383-shares-private-placement-4-209-994-75/). What is the ticker symbol of Rezolute? Rezolute, Inc. trades under the ticker RZLT on NASDAQ. Where is Rezolute listed? Rezolute, Inc. is listed on NASDAQ. Our directory also records these other listings: LS:A2QEWP; LSX:A2QEWP. What is the SEC CIK of Rezolute? The SEC Central Index Key (CIK) for Rezolute, Inc. is 1509261. Its filings are on SEC EDGAR. How many shares does Rezolute have outstanding? 96,722,333 shares as of 2026-09-21, per the cover page of its 10-K filed 2026-09-24. Which country or territory is Rezolute listed under? Our directory records Rezolute, Inc. under United States. What does Rezolute do? Our directory classifies Rezolute, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Rezolute? The ISIN recorded for Rezolute, Inc. is US76200L3096. Does aibio.space cover Rezolute? aibio.space lists Rezolute, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Rezolute incorporated? SEC records list its state or country of incorporation as NV. What does Rezolute develop? Rezolute, Inc. is a late-stage rare disease company developing therapies for refractory and debilitating hypoglycemia associated with hyperinsulinism (HI). Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds an allosteric site on the insulin receptor. What is ersodetug from Rezolute? ersodetug: Allosteric insulin receptor antibody for refractory hypoglycemia caused by hyperinsulinism Stage: Phase 3 sunRIZE did not meet primary endpoint; FDA reviewing submission. Is Rezolute profitable? Rezolute, Inc. reported a net loss of $77.6 million for the fiscal year ended Jun 30, 2026, and used $64.6 million of cash in operations, per its annual report to the SEC. How much does Rezolute spend on research and development? $53.8 million in the fiscal year ended Jun 30, 2026, per its annual report. How much cash does Rezolute have? $107.8 million in cash and short-term investments at Jun 30, 2026, per its 10-K. ## Investor discussion: Rezolute Members talk about Rezolute (RZLT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Rezolute, newest first. Each line links the filing it comes from. 1. 2025-10-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,5.02). [Source](https://www.sec.gov/Archives/edgar/data/1509261/000110465925101282/tm2529201d1_8k.htm) 2. 2025-08-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1509261/000110465925080473/tm2523938d1_ex99-1.htm) 3. 2025-06-13 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1509261/000110465925059336/tm2518002d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RZLT on TradingView](https://www.tradingview.com/symbols/NASDAQ-RZLT/). ## SEC filings and registration - **SEC name**: Rezolute, Inc. - **CIK**: 1509261 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RZLT (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065 - **Phone**: 650-206-4507 - **Shares outstanding**: 96,722,333 as of 2026-09-21 (10-K filed 2026-09-24) - **Former names**: AntriaBio, Inc.; FITS MY STYLE INC ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1509261/000110465926117868/rzlt-20261202xdef14a.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1509261/000110465926115874/tm2627620d1_8k.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1509261/000110465926113503/tm2626976d1_8k.htm) filed 2026-10-05 - [10-K](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm) filed 2026-09-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_8k.htm) filed 2026-09-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/tm2616579d1_8k.htm) filed 2026-06-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1509261/000110465926059422/rzlt-20260331x10q.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/tm2614169d1_8k.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001509261), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Rezolute, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RZLT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Rezolute, Inc. - **Ticker**: RZLT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US76200L3096 - **Other listed symbols**: LS:A2QEWP; LSX:A2QEWP - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RZLT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/rezolute/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rezolute (RZLT) news: offering", 2026-10-31, https://aibio.space/companies/rezolute/